Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Bol KF, Schreibelt G, Bloemendal M, van Willigen WW, Hins-de Bree S, de Goede AL, de Boer AJ, Bos KJH, Duiveman-de Boer T, Olde Nordkamp MAM, van Oorschot TGM, Popelier CJ, Pots JM, Scharenborg NM, van de Rakt MWMM, de Ruiter V, van Meeteren WS, van Rossum MM, Croockewit SJ, Koeneman BJ, Creemers JHA, Wortel IMN, Angerer C, Brüning M, Petry K, Dzionek A, van der Veldt AA, van Grünhagen DJ, Werner JEM, Bonenkamp JJ, Haanen JBAG, Boers-Sonderen MJ, Koornstra RHT, Boomsma MF, Aarntzen EHJ, Gotthardt M, Nagarajah J, de Witte TJM, Figdor CG, de Wilt JHW, Textor J, de Groot JWB, Gerritsen WR, de Vries IJM. Bol KF, et al. Among authors: van rossum mm. Nat Commun. 2024 Feb 23;15(1):1632. doi: 10.1038/s41467-024-45358-0. Nat Commun. 2024. PMID: 38395969 Free PMC article. Clinical Trial.
Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients.
Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Boudewijns S, et al. Among authors: van de rakt mw, van der graaf wt, van oorschot tg, van meeteren ws, van rossum mm. Oncoimmunology. 2016 May 31;5(7):e1191732. doi: 10.1080/2162402X.2016.1191732. eCollection 2016 Jul. Oncoimmunology. 2016. PMID: 27622047 Free PMC article.
Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients.
Bloemendal M, Bol KF, Boudewijns S, Gorris MAJ, de Wilt JHW, Croockewit SAJ, van Rossum MM, de Goede AL, Petry K, Koornstra RHT, Figdor C, Gerritsen WR, Schreibelt G, de Vries IJM. Bloemendal M, et al. Among authors: van rossum mm. Oncoimmunology. 2021 Dec 30;11(1):2015113. doi: 10.1080/2162402X.2021.2015113. eCollection 2022. Oncoimmunology. 2021. PMID: 36524210 Free PMC article. Clinical Trial.
Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, van Rossum MM, Mus R, Oyen WJ, Boerman OC, Lucas S, Adema GJ, Punt CJ, Figdor CG. Lesterhuis WJ, et al. Among authors: van de rakt mw, van rossum mm. Clin Cancer Res. 2011 Sep 1;17(17):5725-35. doi: 10.1158/1078-0432.CCR-11-1261. Epub 2011 Jul 19. Clin Cancer Res. 2011. PMID: 21771874 Free article.
Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients.
Bol KF, Figdor CG, Aarntzen EH, Welzen ME, van Rossum MM, Blokx WA, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Mus RD, Croockewit SA, Jacobs JF, Schuler G, Neyns B, Austyn JM, Punt CJ, Schreibelt G, de Vries IJ. Bol KF, et al. Among authors: van de rakt mw, van oorschot tg, van rossum mm. Oncoimmunology. 2015 Apr 1;4(8):e1019197. doi: 10.1080/2162402X.2015.1019197. eCollection 2015 Aug. Oncoimmunology. 2015. PMID: 26405571 Free PMC article.
Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.
Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EH, Duiveman-de Boer T, van de Rakt MW, Scharenborg NM, de Boer AJ, Pots JM, Olde Nordkamp MA, van Oorschot TG, Tel J, Winkels G, Petry K, Blokx WA, van Rossum MM, Welzen ME, Mus RD, Croockewit SA, Koornstra RH, Jacobs JF, Kelderman S, Blank CU, Gerritsen WR, Punt CJ, Figdor CG, de Vries IJ. Schreibelt G, et al. Among authors: van de rakt mw, van oorschot tg, van rossum mm. Clin Cancer Res. 2016 May 1;22(9):2155-66. doi: 10.1158/1078-0432.CCR-15-2205. Epub 2015 Dec 28. Clin Cancer Res. 2016. PMID: 26712687 Clinical Trial.
Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
Bol KF, Aarntzen EH, Pots JM, Olde Nordkamp MA, van de Rakt MW, Scharenborg NM, de Boer AJ, van Oorschot TG, Croockewit SA, Blokx WA, Oyen WJ, Boerman OC, Mus RD, van Rossum MM, van der Graaf CA, Punt CJ, Adema GJ, Figdor CG, de Vries IJ, Schreibelt G. Bol KF, et al. Among authors: van de rakt mw, van der graaf ca, van oorschot tg, van rossum mm. Cancer Immunol Immunother. 2016 Mar;65(3):327-39. doi: 10.1007/s00262-016-1796-7. Epub 2016 Feb 10. Cancer Immunol Immunother. 2016. PMID: 26861670 Free PMC article.
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.
Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kiliç E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ. Bol KF, et al. Among authors: van den bosch t, van der graaf wt, van rossum mm. Ophthalmology. 2016 Oct;123(10):2265-7. doi: 10.1016/j.ophtha.2016.06.027. Epub 2016 Jul 29. Ophthalmology. 2016. PMID: 27476772 Clinical Trial. No abstract available.
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer.
Westdorp H, Creemers JHA, van Oort IM, Schreibelt G, Gorris MAJ, Mehra N, Simons M, de Goede AL, van Rossum MM, Croockewit AJ, Figdor CG, Witjes JA, Aarntzen EHJG, Mus RDM, Brüning M, Petry K, Gotthardt M, Barentsz JO, de Vries IJM, Gerritsen WR. Westdorp H, et al. Among authors: van rossum mm. J Immunother Cancer. 2019 Nov 14;7(1):302. doi: 10.1186/s40425-019-0787-6. J Immunother Cancer. 2019. PMID: 31727154 Free PMC article. Clinical Trial.
79 results